When you consider some of the valuations in the stem cell space, buying Hemostemix stock appears to be almost a no brainer. It is abundantly clear based on peer valuations the stock is severely undervalued. While the below noted company uses a different system and method, they are only in Phase 1 and have clinical results based on a single patient. Hemostemix is more evolved and has a market capitalization of $23 million Cdn vs a current valuation of $8.7 billion USD for Fate Therapeutics. This disconnect creates an insane ROI scenario. I actually cannot find a better opportunity. I imagine I won’t be the only one who recognizes this calculated chance at potential wealth creation. Every smallcap stock has inherent risk but each investor must make their own determination based on a strengths and weaknesses analysis. I would love to hear from other investors about possible negatives outside of the 20:1 consolidation which I actually view as a positive.
Fate Therapeutics (NASDAQ:FATE) is a clinical-stage biotechnology company specializing in engineered cell therapies for cancer. Its stock price has shot up from about $20 per share near the beginning of 2020 to over $95 per share following the release of trial data at ASH (American Society of Hematology annual meeting). That gave it a market capitalization of near $8 billion, which is quite remarkable since it is based largely on Phase 1, early clinical-stage data. In this article, I will look at the recently revealed data sets, Fate's platform, and the rest of its pipeline. Then, I will examine whether, at current prices, it might still be undervalued for long-term investors.
Fate Therapeutics jumped 9% after ASH and more than quadrupled in 2020. Natural Killer cell therapy FT516 and CAR NK therapy FT596 had positive results.Dec 18, 2020
seekingalpha.com › article › 43...
Fate Therapeutics Jumped On Supportive Trial Data (NASDAQ ...